Experts dedicated to innovation

Our programs

Therapeutic programs

DIVINCELL’s Approach for the Future of RNA-based Treatment – getting to the root of the problem

Restoring, replacing or removal of the culprit mutated genes as a strategy to treat cancers remains an untapped area. DIVINCELL’s approach to targeting Tumor Suppressor Genes and Oncogenes can provide a major advance in treatment of cancer. DIVINCELL scientists have demonstrated these approaches in numerous studies in therapeutic cancer models including lung cancer, colorectal cancer, pancreatic cancer and osteosarcoma against mutated targets like P53, BRCA1 and KRAS utilizing the selective tumor targeting ability of the PEP-NPTM technology.
In vivo CAR T generation by selectively targeting T-cells in the body with the PEP-NPTM technology produces anti-CD19 CAR T cells in vivo resulting in the depletion of B cells responsible for hematological malignancies and certain autoimmune diseases. This approach has advantages over lentiviral or lipid nanoparticle vectors which are limited by challenges in repeat dosing due to immunogenicity or liver toxicity.

Tumor Suppressor Rescue
TSG-RescueTM

Restores the lost function of mutated tumor suppressor genes like p53, the “Guardian of the Genome,” the most broadly mutated Tumor Suppressor occurring in 50% of all cancers, a major driver, and a marker of poor prognosis, with no successful targeting strategy for more than 500,000 new individuals worldwide every year.

Our technology delivers functional RNA exactly where it’s needed, preventing redundancy and resistance.

This new therapeutic approach to treat p53 mutations and alterations results in strong inhibition and regression of tumors in animal models as a single-agent therapy as well as in combination with other cancer therapies.
Our strategy can lead to a broad pipeline first targeting p53 and then moving to other Tumor Suppressors.

Oncogene Editing/Deletion
ONCOEDITTM

Uses gene editing or silencing to eliminate oncogene mutations (e.g. KRAS G12D/V/C), confronting uncontrolled proliferation at the source. KRAS is the most frequently mutated Oncogene and a major driver of cancers with approximately 500 000 new individuals worldwide every year with G12D or G12V mutations.

Small molecules are in development but drug resistance remains a common problem.
This new root-cause approach results in strong inhibition and regression of tumors with very few treatments, halts cancer’s development of alternate signaling pathways, preventing resistance that plagues small molecule and downstream therapies.

Our approach to targeted oncogene deletion can lead to a broad pipeline, first targeting KRAS mutations and then moving to other Oncogenes.

IN VIVO CAR-T in vivo
PEP-CARTM

Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized hematologic cancer treatment and shows promise for autoimmune diseases, but ex vivo CAR T faces challenges including complex manufacturing, scalability issues, high costs, and safety concerns from lymphodepletion.

In vivo CAR T generation with lentiviral or lipid nanoparticle vectors expands accessibility but is limited by challenges in repeat dosing due to immunogenicity and liver toxicity. DIVINCELL’s peptide-based nanocarrier PEP-CARTM, targeting CD3 receptors, enables efficient in vivo engineering of T cells to express anti-CD19 CAR with demonstrated efficacy in mice—rapid depletion of CD19+ B cells and safe, repeated dosing for long-term therapy.

We are harnessing the power of our PEP-NPTM platform to generate chimeric antigen receptor T-cell (CAR-T) therapies in vivo, thus avoiding the need to produce these cells outside the body and enabling considerable time savings and simplification of treatments

PEP-CARTM offers a scalable, accessible alternative likely to surpass ex vivo approaches, with broad applicability in hematologic cancers and autoimmune diseases, and flexible targeting potential beyond CD19 to expand immune cell therapies.

DIVINCELL’s therapies strike at the core genetic drivers of disease—ending the cycle of resistance and relapse, and creating possibilities where indirect therapies cannot.

pipeline

A therapeutic pipeline redefining oncology

We are developing transformational therapies in the fields of oncology, immuno-oncology, and genetic disorders.
DIVINCELL SAS, in collaboration with Aanastra Inc, has built a comprehensive intellectual property portfolio encompassing key aspects of the nucleic acid and protein delivery strategy using PEP-NPTM platform , in conjunction with proprietary targeting and manufacturing technologies.